GlaxoSmithKline Plc. (GSK: Quote,GSK.L) and Theravance Inc. (THRX: Quote) announced positive results from a phase III efficacy and safety study of fluticasone furoate “FF"/vilanterol “VI” designed to support a potential filing for an asthma indication for adults in the US. For the pre-specified primary endpoint of 0-24 hour weighted mean forced expiratory volume in one second (FEV1), FF/VI 100/25mcg demonstrated a statistically significant improvement in lung function compared with FF 100mcg (108ml, 95% CI 45, 171 p < 0.001) at the end of the 12 week treatment period.
Help employers find you! Check out all the jobs and post your resume.
